Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.
Weitere Episoden von „Kidney360“



Verpasse keine Episode von “Kidney360” und abonniere ihn in der kostenlosen GetPodcast App.








